Bulk IgG glycosylation predicts COVID-19 severity and vaccine antibody response

Michelle K. Ash, Pavan P. Bhimalli, Byoung Kyu Cho, Basil Baby Mattamana, Stéphanie Gambut, Imad Tarhoni, Cristina L. Fhied, Anjelica F. Reyes, Samantha J. Welninski, Jaison Arivalagan, Fernanda Negrão, Renu Goel, Todd L. Beck, Thomas J. Hope, Beverly E. Sha, Young Ah Goo, Lena Al-Harthi, João I. Mamede, Jeffrey A. Borgia, Neil L. KelleherJeffrey R. Schneider

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Although vaccination efforts have expanded, there are still gaps in our understanding surrounding the immune response to SARS-CoV-2. Measuring IgG Fc glycosylation provides insight into an infected individual's inflammatory state, among other functions. We set out to interrogate bulk IgG glycosylation changes from SARS-CoV-2 infection and vaccination, using plasma from mild or hospitalized COVID-19 patients, and from vaccinated individuals. Inflammatory glycans are elevated in hospitalized COVID-19 patients and increase over time, while mild patients have anti-inflammatory glycans that increase over time, including increased sialic acid correlating with RBD antibody levels. Vaccinated individuals with low RBD antibody levels and low neutralization have the same IgG glycan traits as hospitalized COVID-19 patients. In addition, a small vaccinated cohort reveals a decrease in inflammatory glycans associated with peak IgG concentrations and neutralization. This report characterizes the bulk IgG glycome associated with COVID-19 severity and vaccine responsiveness and can help guide future studies into SARS-CoV-2 protective immunity.

Original languageEnglish
Article number111799
JournalCell Reports
Volume41
Issue number11
DOIs
StatePublished - Dec 13 2022

Keywords

  • COVID-19
  • CP: Immunology
  • SARS-CoV-2, IgG, RBD, Nucleocapsid, vaccination, infection, neutralization, inflammation
  • antibodies
  • glycosylation

Fingerprint

Dive into the research topics of 'Bulk IgG glycosylation predicts COVID-19 severity and vaccine antibody response'. Together they form a unique fingerprint.

Cite this